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Abstract: Physiological training responses depend on sympathetic (SNS) and parasympathetic
nervous system (PNS) balance. This activity can be measured using heart rate variability (HRV). Such a
measurement method can favor individualized training planning to improve athletes’ performance.
Recently, HRV-guided training has been implemented both on professional and amateur sportsmen
and sportswomen with varied results. There is a dearth of studies involving professional endurance
athletes following a defined HRV-guided training protocol. The objectives of the proposed protocol are:
(i) to determine changes in the performance of high-level athletes after following an HRV-guided or a
traditional training period and (ii) to determine differences in the athletes’ performance after following
both training protocols. This will be a 12-week cluster-randomized controlled protocol in which
professional athletes will be assigned to an HRV-based training group (HRV-G) or a traditional-based
training group (TRAD-G). TRAD-G will train according to a predefined training program. HRV-G
training will depend on the athletes’ daily HRV. The maximal oxygen uptake (VO2max) attained
in an incremental treadmill test will be considered as the primary outcome. It is expected that
this HRV-guided training protocol will improve functional performance in the high-level athletes,
achieving better results than a traditional training method, and thus providing a good strategy for
coaches of high-level athletes.
Keywords: HRV; endurance training; training performance; high level athletes; VO2max; running
1. Introduction
It is known that training is essential for improving physical performance [1] and that optimizing
training for performance improvement in athletes is an important area of research within exercise
physiology and sports medicine [2–4]. In this regard, different training methods for performance
improvement have been tried and tested, such as intensified training [2,5,6] and submaximal tests [7].
However, it is also recognized that using the same standardized training program for a group of athletes
can provoke a wide range of reactions in terms of performance and physiological adaptations [8,9].
As stated by Schmitt, Willis, Fardel, Coulmy, and Millet [10], an important component of the
interindividual variability in physiological responses to standardized training is related to the balance
between the parasympathetic (PNS) and sympathetic (SNS) activity of the autonomic nervous system
(ANS) [11,12]. Heart rate variability (HRV) is one of the indicators that allows the noninvasive study
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of autonomic nervous system activity in its sympathetic and parasympathetic branches [13,14]. HRV is
understood as the variation in the time interval between two consecutive heartbeats. It is obtained by
calculating the time interval that elapses between two consecutive R waves (i.e., RR interval fluctuation)
on an electrocardiogram (ECG) [15]. The period between beats is not constant; consequently, high
HRV values are associated with an efficient ANS, which promotes behavioral adaptation and cognitive
flexibility during stress [16], whilst low HRV values are indicative of an inefficient ANS, resulting in
maladaptive responses to stress and perceived threats [15]. Furthermore, HRV is considered to be an
indicator of cardiovascular health level [17].
Given that the SNS is responsible for changes in heart rate (HR) due to stress, and that the HR
is one of the first parameters used to control the body’s functional capacity [18], HRV analysis has
been established as a useful method for assessing the heart’s ability to adapt to both endogenous and
exogenous loads [19], and can be used for the individual assessment of responses to training loads.
Indeed, in recent years, HRV has been used to analyze these imbalances between SNS and PNS in
athletes [20] and to evaluate different aspects related to training [21] such as exercise intensity and
duration [22], recovery and overtraining [23], training load [24] or psychophysiological profiles [25].
The control of training based on HRV, as an indicator of the precompetitive physical and
psychological state in athletes, enables coaches and scientists to use these HRV records to adapt
the recovery and training loads to each athlete in search of a better sports result. As indicated
by Ortigosa-Márquez, Reigal, Carranque, and Hernández-Mendo [26], high HRV values indicate
more parasympathetic than sympathetic activation in an athlete and, therefore, better recovery and
preparation for dealing with high-intensity training sessions.
Traditionally, HRV has been measured with ECG [14]. One of the ways of quantifying HRV is
through rMSSD (the root mean square of successive differences between adjacent RR intervals) [26]
since it is a temporal statistical parameter that reports those variations occurring over the short term
between RR intervals [27] and it is used to observe the influence of the SNP on the cardiovascular
system [18]. Currently, there are other validated tools for determining HRV that facilitate measurement,
such as the Kubios HRV, Elite HRV, Mobile Lab and HRV4Training applications (apps).
In recent years, experimental studies have been carried out evaluating HRV-guided training
in endurance athletes. These studies have been conducted both on elite athletes in sports such as
cycling [24] and skiing [10], and with amateur endurance athletes [28–31]. One should take into
account the scarcity of studies that have been published to date, especially on elite-level endurance
athletes, as well as the absence of a common protocol to follow in this type of research.
The protocol proposed in the present study contributes to the scientific literature in this field
in several ways: (i) it proposes research focused on elite athletes, a sample population for which
only two experimental studies have been carried out to date; (ii) the protocol is intended to research
endurance runners, for which we are not aware of any research having been carried out on this type of
sample and with these characteristics at the international level. Therefore, it is a novel study aiming to
provide empirical support for HRV-guided training in long-distance runners, adapting daily training
to the physiological responses of each individual athlete. The performance of these athletes could be
compared to that of another group of long-distance runners who carry out traditional training over the
same period of time.
Until just a few years ago, conducting research of this type, involving daily HRV measurements on
each athlete and then adapting training based on these data, was only possible with the collaboration
of high-cost laboratories. This study tests the use of noninvasive, commercial, low-cost and publicly
accessible technology to evaluate the physiological responses obtained by adapting training to HRV.
Based on everything described above, we hypothesize that HRV-guided training will: (i) improve
functional performance in high-level athletes and (ii) produce better performance results than a
traditional training method. The objectives of the proposed protocol are: (i) to determine changes in
the performance of high-level athletes after following an HRV-guided or a traditional training period,
and (ii) to determine differences in the athletes’ performance after following both training protocols.
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This will be a 12-week cluster-randomized controlled trial protocol in which professional
athletes are assigned to either an HRV-based training group (HRV-G) or a traditional-based training
group (TRAD-G). A block randomization method will be chosen to randomly assign participants to
interventions in equally sized sample groups. This protocol has been designed following the Standard
Protocol Items: Recommendations for Interventional Trials (SPIRIT) Statement [32]. To describe
the intervention, the TIDieR (Template for Intervention Description and Replication) checklist by
Hoffmann et al. [33] has been used.
2. Materials and Methods
2.1. Study Setting
To detect an intervention-related effect in professional athletes, other studies with similar
protocols [24,31] compared athletes from two clubs or associations. Similarly, our sample will
comprise athletes from two sport institutions in Almería (Spain): the C.D. Atletas de Almería, based in
the city of Almería (Spain) and the Asociación Espeleológica Velezana, based in Vélez Rubio (Spain).
2.2. Eligibility Criteria
The inclusion criteria for participating in the program will be: (i) to belong to the Spanish Athletics
Federation; (ii) to have been training and competing in Spanish Athletics Federation competitions
for at least two years; and iii) to be in the first third of the classification for the last five races of the
previous season. Regarding the exclusion criteria, the following will be taken into account: (i) having
cardiovascular pathologies, abnormal blood pressure parameters or diagnosed respiratory problems;
(ii) being treated for psychological problems, or regularly taking a drug(s) that has a direct or indirect
effect on the nervous system (e.g., anxiolytics, antidepressants or neuroleptics); (iii) substance use
that is not permitted by the International Association of Athletics Federations (IAAF); (iv) occasional
consumption of medication for a disease related to the cardiorespiratory system (e.g., influenza) that
might alter performance and (v) not performing at least 90% of the workouts during the intervention.
The trial steering members will be responsible for checking that the subjects interviewed meet
the inclusion criteria. The Spanish Athletics Federation’s medical team will certify that the subjects
do not meet any of the exclusion criteria. After being informed of the study design and potential
risks, all athletes will sign a written informed consent document. The model consent form is shown in
Appendix A.
2.3. Interventions
Based on the methodology used by Javaloyes et al. [24] and Vesterinen et al. [31], the intervention
will be divided into two training periods for both study groups (HRV-G and TRAD-G): a four-week
preparation period (PR) and an eight-week training period (TR). Both will maintain the weekly training
volume. The training carried out will mainly be running. The PR period will be common to both
groups and will be a familiarization phase for the training sessions and their intensities. During this
period, the training intensity will gradually increase for the first three weeks and then decrease in the
fourth week. This will mean three weeks of overloading and one week of recovery (3:1). The training
to be carried out by the athletes is presented in more detail in Table 1. In the TR period, each group
will carry out the corresponding intervention. The TRAD-G group will train according to a predefined
training program, which will include sessions carried out at low intensity (approximately 50% of
the total), and other sessions of moderate and high intensity, with a structure similar to that carried
out during the PR period (Table 2). The training prescribed to the HRV-G group will depend on the
subjects’ HRV, in accordance with authors such as Javaloyes et al. [24], Kiviniemi, Hautala, Kinnunen,
and Tulppo [34], and Lamberts, Swart, Noakes, and Lambert [35].
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Table 1. Periodization and training distribution for the heart rate variability group (HRV-G) and
traditional-based training group (TRAD-G) during the preparation period (PR).
Weeks High Intensity Moderate Intensity Low Intensity
1 90 min between VT1and VT2
3–4 sessions between 30
and 35 min below VT1
2 4 × 12 min >VT2/3-min rest
90 min between VT1
and VT2
2–3 sessions between 30
and 35 min below VT1
3 50 min at VT2 4 × 12 min >VT2/3-min rest
90 min between VT1
and VT2
2–3 sessions between 30
and 35 min below VT1
4 3–4 sessions between 30and 35 min below VT1
Note: VT1 = first ventilatory threshold; VT2 = second ventilatory threshold. High-intensity and moderate-intensity
sessions will be performed with a 15- to 20-min warm up and 20 min of cooling down.
Table 2. Periodization and training distribution for TRAD-G during training period (TR).
Weeks High Intensity Moderate Intensity Low Intensity
5 50 min at VT2 3–4 sessions between 30and 35 min below VT1
6 4 × 12 min >VT2/3-min rest
90 min between VT1
and VT2
2–3 sessions between 30
and 35 min below VT1
7 50 min at VT2 4 × 12 min >VT2/3-min rest
90 min between VT1
and VT2
2–3 sessions between 30
and 35 min below VT1
8 3–4 sessions between 30and 35 min below VT1
9 50 min al VT2 3–4 sessions between 30and 35 min below VT1
10 90 min between VT1and VT2
2–3 sessions between 30
and 35 min below VT1
11 50 min al VT2 4 × 12 min >VT2/3-min rest
90 min between VT1
and VT2
2–3 sessions between 30
and 35 min below VT1
12 3–4 sessions between 30and 35 min below VT1
Note: VT1 = first ventilatory threshold; VT2 = second ventilatory threshold. High-intensity and moderate-intensity
sessions will be performed with a 15- to 20-min warm up and 20 min of cooling down. Approximately 50% of the
total sessions will be at low intensity.
To quantify the HRV, a Smartphone application known as “HRV4Training” (see http://www.
hrv4training.com/) will be used. This tool has been validated by Plews et al. [36], showing a low
typical estimate error (CV% (90% CI) = 3.8 (3.1; 5.0)) and a clear electrocardiographical correlation
(r = 1.00 (1.00; 1.00)). It provides the root mean sum of the successive differences between R – R
intervals (rMSSD) data using photoplethysmography. rMSSD is more suitable and reliable than other
indexes [13,37]; nonetheless, the HRV data will be transformed by taking the natural logarithm, thus
allowing parametric statistical comparisons that assume a normal distribution. In this way, a 7-day
rolling average will be calculated (LnrMSSD7-d). The PR period will be used as a standardized phase
to obtain the baseline LnrMSSD7-d and its range of normality (upper and lower limits). Following the
indications of Plews, Laursen, Kilding, and Buchheit [38], this will be calculated as the mean ± 0.5 × SD.
During the TR period, the LnrMSSD7-d will be calculated daily in order to adapt the training prescribed
to the HRV-G athletes. Moreover, the range of normality will be updated weekly. If the LnrMSSD7-d is
within the range of normality, the athletes will perform a moderate or high-intensity session. If the
weekly LnrMSSD7-d average falls below the normal range, a low intensity workout or rest will be
undertaken. Athletes will perform a maximum of two consecutive sessions of moderate or high
intensity; likewise, they will not accumulate more than two consecutive rest sessions. The modified
scheme of Kiviniemi et al. [34] presented in Figure 1 will be followed.
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2.4. Outcomes
The primary outcome of this study will be the maximal oxygen uptake (VO2max) obtained in an
incremental treadmill test. The secondary outcomes will be: the maximal speed in m/s, maximal heart
rate, respiratory exchange ratio, ventilatory thresholds (VT1 and VT2) and their derived speed, heart
rate, respiratory exchange ratio and VO2 obtained in the incremental treadmill test. Other measurements
considered as secondary outcomes will be: the time, speed, heart rate, rating of perceived exertion
(RPE) and lactate in the 3000 m running test. Body composition and rMSSD will be considered as
other variables.
Measurements will be taken before and after the training period, which will correspond to weeks 5
(pretest) and 12 (post-test). Over the assessment weeks, care will be taken that participants do not carry
out any high-intensity training sessions. Each assessment week will consist of two testing sessions
with a 48-h recovery period. The first testing session will include maximal graded exercise test and
body composition measurements. In the second testing session, athletes will perform a 3000 m running
test. The rMSSD will be measured daily, as explained in the intervention section.
The incremental treadmill test will be performed by the Physical Exercise and Human Performance
Research Group at the University of Murcia (Spain). This is a more objective way of determining
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physical fitness and represents the maximal performance capacity of an individual [39]. First, with the
athlete in the supine position, a cardiovascular examination will be carried out at rest by means of
cardiac auscultation, blood pressure and an electrocardiogram (ECG). The electrodes for recording the
ECG and heart rate will be kept in place throughout the test. The Cardioline Cube® electrocardiograph
will be used. To perform the incremental treadmill test, the Runner srl (Cavezzo Italy) treadmill will
be used, as it was in other studies such as Ballesta-García, Martínez-González-Moro, Ramos-Campo,
and Carrasco-Poyatos [40]. Similar to other studies, such as Nuuttila et al. [30] or Vesterinen et al. [31],
a prior 2-min aerobic warm up will be performed at 6 km/h. The test itself will start at a velocity of
7 km/h. The speed will be increased by 0.1 km/h every 6 s. The incline will remain at 1% throughout the
test. The athletes will be encouraged to perform at maximum effort. The test will end when the subject
can no longer run; the subject will indicate this with a hand gesture. The recovery phase will then
begin at 4km/h for 3 min followed by rest for a further 2 min. The tests will be considered maximal and
valid when the theoretical heart rate (220-age) exceeds 85% and the respiratory exchange ratio (RER) is
greater than 1.15 [41]. During the stress test, the subjects will breathe through a mask connected to a gas
analyzer (Metalyzer 3b®, Cortex, Leipzig, Germany). All gas exchange parameters will be measured
breath-by-breath and averaged every 30 s. The VO2max will be defined as the oxygen consumption
plateau [42]. The aerobic (VT1) and anaerobic (VT2) thresholds will be determined. Before each test,
the gas analyzer will be manually calibrated. The test’s maximal speed (Vmax), maximal heart rate
(HRmax), and respiratory exchange ratio (RER) will be recorded. The Vmax or HRmax will be defined
as the highest speed, or heart rate, reached for a finished stage. The speed, heart rate, respiratory
exchange ratio and VO2 at each ventilatory threshold will also be recorded as VVT1, VVT2, HRVT1,
HRVT2, RERVT1, RERVT2, VO2VT1, and VO2VT2, respectively. All tests will be carried out under similar
environmental conditions (an ambient temperature of 20–22 degrees).
As in other studies [30,43], the 3000 m running test will be conducted individually on a 400 m
outdoor running track. Participants will be instructed to run at their maximum speed. Before the test,
a 15 min standardized aerobic warm-up will be performed, consisting of running at a low to moderate
intensity. Capillary blood samples (5 µL) for blood lactate concentration analysis will be taken from
the fingertip using a Scout+ analyzer (SensLab GmbH, Leipzig, Germany). Lactate is considered a
useful indicator for measuring the metabolic cost and intensity of effort in aerobic-anaerobic sports [44].
Following Ribas [45], it will be considered in this test to relate it to running intensity. Lactate samples
will be taken at four different points in time, in accordance with Rodríguez and Valero [46]: (i) just
before the test (Lactatepre), (ii) just after the test (Lactatepost), (iii) 3 min after the test (Lactatepost3)
and iv) 5 min after the test (Lactatepost5). Other variables, such as heart rate, time, speed, and rated
perceived exertion (RPE), will also be measured. Heart rate will be recorded at five different points in
time: (i) just before the test (HRpre), (ii) just after the test (HRpost), (iii) 1 min after the test (HRpost1),
(iv) 3 min after the test (HRpost3) and v) 5 min after the test (HRpost5). The time will be recorded every
1000 m at three different points in time: (i) after running 1000 m, (ii) after running 2000 m and (iii) after
running 3000 m (right at the end of the test). The speed will be calculated from these three points using
the formula: speed = distance in m/time in seconds. The RPE will be measured at the end of the test
using the modified Börg CR-10 scale of perceived exertion [47]. According to the authors, a 0 rating
corresponds to rest; a 3 rating to moderate intensity; a 5 rating to hard intensity; a 7 rating to very hard
intensity; and a 10 rating to maximal intensity. This tool has recently been determined as a stand-alone
method for training load monitoring purposes in several sports and physical activities with men and
women in different age categories (children, adolescents and adults) at various expertise levels [48].
Body composition will be analyzed just before the treadmill test using the InBody120 analyzer
(Biospace Co. Ltd., Seoul, South Korea). Height will be measured using a measuring rod (Seca 213),
and the body mass index (BMI) will be calculated according to the formula: BMI = kg/m2.
The time schedule for enrolment, interventions and assessments is shown in Figure 2.
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2.5. Sample Size and Power
Calculations to establish the sample size will be performed using RStudio 3.15.0 software (PBC,
Boston, USA). The significance level will be set at p ≤ 0.05. According to the mean standard deviation
established for VO2max in a previous study [31] (SD = 1.5 mL/kg/min) and an estimated error (d) of 1.1,
a valid sample size providing a 95% confidence interval (CI) in each group will be 7 (n = CI2 × d2/SD2).
Thus, a final sample size of 7 for each group will provide a power of 93% if between and within a
variance of 2.
2.6. Recruitment
Each club or association involved in athletics in Almería (Spain) will be screened to identify the
percentage of high-level or professionally federated athletes. When there are at least 7 high-level or
professionally federated athletes, the club/association officers will be contacted by telephone to inform
them of the study objective. Once they agree, an informative talk will be carried out with the athletes
and the coach to inform them of the study objective, the time period in which it will take place, and the
required commitment by the athletes to measure their daily HRV according to the established protocol,
to attend the pre and post-test sessions and to attend at least 90% of the training sessions. The coaches
will be informed of the required commitment to adapt each athlete’s training session to the daily HRV
score if their club is randomized into the HRV-G group. If they agree to participate, then they will have
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to sign the written consent and meet the eligibility criteria necessary to be recruited into the study.
The recruitment process will be conducted by the trial steering members.
2.7. Allocation and Blinding
A block randomization method will be used to allocate participants to the groups, which will
contain equal sample sizes. The block size will be determined by the data monitoring committee
according to the statistical power provided. Blocks will be chosen randomly by tossing a coin to
determine the participants’ assignment into the groups. This procedure will be carried out by the data
monitoring committee. The athletes and the data monitoring committee will be blinded to the exercise
group assignment.
2.8. Data Analysis
Data will be analyzed using Jamovi (Jamovi Project 2018, version 0.9.1.7, Sydney, Australia)
and RStudio 3.15.0 software (PBC, Boston, MA, USA). Prior to data analysis, the Shapiro Wilk test
and the Levene test will be performed to determine the normal distribution of the variables and the
homogeneity of variance. Descriptive data will be reported as mean ± SD and range. All the data
will be analyzed based on the intention-to-treat principle (last observation carried forward). If the
sample is normally distributed, Student’s t-test will be calculated to compare variables before and after
the intervention. For a variable to be considered as having a normal distribution, 95% of values will
have to be within two standard deviations of the mean. If the sample is nonparametric, the U-Mann
Whitney test will be used to compare variables before and after the intervention. The standardized
mean differences (Cohen’s effect size) will be calculated together with the 95% confidence intervals [49].
The effect sizes (ES) will be calculated using Cohen’s d [49]. The relationship between variables will be
assessed using the Pearson r correlation coefficient. If r is higher than 0.7, the determination coefficient
(r2) will be used to determine the percentage of Y variation with regard to the X variation. Significance
will be accepted at p ≤ 0.05.
2.9. Monitoring
A data monitoring committee will be set up during the study recruitment period. Interim analyses
will be supplied to the committee in strict confidence, together with any other analyses that the
committee may request. Based on the data monitoring committee’s advice, the trial steering members
will decide whether or not to modify the trial intake.
In our study, an adverse event will be defined as any untoward medical occurrence in a subject
without regard to the possibility of a causal relationship. Adverse events will be collected after the
subject has provided consent and enrolled in the study. If a subject experiences an adverse event
after the informed consent document is signed (entry) but the subject has not started to receive study
intervention, the event will be reported as not being related to the study’s exercise program. For this
study, the following will be considered serious adverse events: severe or permanent disability, use of
prohibited substances and any other significant hazard as determined by the study members. Serious
adverse events occurring after a subject has stopped participating in the study will not be reported
unless the researchers feel that the event may have been caused by the study protocol procedure.
2.10. Ethics and Dissemination
This protocol, the informed consent template contained in Appendix A and other requested
documents (if any) will be reviewed and approved by the Bioethical Committee at the University of
Almería with respect to the scientific content and compliance with applicable research and human
subject regulations. Following initial review and approval, this protocol will be reviewed by the
researcher at least once a year at Clinicaltrials.org, where it is registered with the ID: NCT04150952.
Any protocol modifications which might have an impact on conducting the study, potentially
benefit a subject or affect a subject’s safety, or change the study objectives, study design, subject
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population, sample sizes, study procedures, along with significant administrative issues, will require
a formal amendment to the protocol. Such an amendment will be agreed upon by the Bioethical
Committee at the University of Almería prior to implementation, and the clubs/associations enrolled
will be notified. Administrative changes to the protocol that are minor corrections, and/or clarifications
having no effect on the way the study is to be conducted, will be agreed upon by the researchers
and documented in a memorandum. The Bioethical Committee at the University of Almería may be
notified of the administrative changes.
All study-related information will be stored securely at the study site. All records that contain
names or other personal identifiers, such as locator forms and informed consent forms, will be stored
separately from the study records and identified by a code number. Forms, lists, logbooks, appointment
books and any other listings that link participant ID numbers to other identifying information will be
stored in a separate, locked file.
3. Discussion
This protocol describes the rationale, design, and methods of an HRV-guided training design for
professional endurance athletes. It will allow accomplishment of a randomized controlled intervention
to determine changes in the performance of high-level athletes after following an HRV-guided or a
traditional training period, Moreover, the differences in the athletes’ performance after following both
training protocols will be determined. To design this protocol with professional endurance athletes, the
guidelines described in Kiviniemi et al. [34] have been followed. This procedure has also been adapted
in other professional sports such as cycling [24,50] and skiing [10], as well as to amateur endurance
athletes [28–31].
This is the first time that this kind of protocol will be applied in endurance elite athletes. After its
implementation, we expect that both high-level athletes groups (HRV-G and TRAD-G) improve:
(i) VO2max and other secondary outcomes measured in the treadmill test (the maximal speed in m/s,
maximal heart rate, respiratory exchange ratio, or ventilatory thresholds), (ii) the time, speed, heart
rate, rating of perceived exertion (RPE) and lactate in the 3000 m running test. Additionally, HRV-G
will be better regarding performance results than the TRAD-G. These findings will suggest that training
guidance balancing the sympathetic and parasympathetic autonomic nervous system leads to greater
athletic performance in endurance athletes compared to standardized prescribed training. This is
relevant for training optimization and for minimizing overuse and reducing injury risk.
4. Conclusions
Experimental research conducted in recent years shows that improvements in variables related
with athletes’ performance (e.g., VO2max) can be obtained through HRV-guided training. However,
accordingly to these studies, results do not allow a consensus to be established regarding the
performance benefits of HRV-guided training for endurance athletes.
From studies carried out until now, this article describes a novel protocol to conduct a randomized
controlled trial with endurance athletes. So far, no other HRV-guided training research has been
conducted with these types of professional athletes. Besides, this protocol proposes to use emergent
technologies in the training and the research fields, such as smartphone applications; in this case,
HRV4training, an app scientifically validated that allows calculation of the daily HRV measurement
for each athlete. Although more research is needed, the implementation of the protocol described here
will contribute to this scientific field of study.
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Appendix A
Mr. Antonio Granero-Gallegos and Ms. María Carrasco-Poyatos, lead researchers on the project:
Physiological and psychological effects from heart rate variability-based training in professional
athletes have informed:
Mr/Ms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ID. . . . .. . . . . . . , about the
present study’s general proceeding, its objectives, duration, purpose, inclusion and exclusion criteria,
associated risks and benefits, as well as the possibility of leaving it without having to give reasons.
In knowledge of all the above, and the measures that will be adopted to protect the participant’s
personal data, according to the current regulations,
I CONSENT to participate in the present research.
Signed: Mr/Ms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ID. . . . .. . . . . . .
Signed: Mr. Antonio Granero-Gallegos, ID 23245990M and Ms. María-Carrasco-Poyatos,
ID 75096834V
Project Leading Researche.
Antonio Granero-Gallegos María Carrasco-Poyatos
References
1. Hostrup, M.; Bangsbo, J. Limitations in intense exercise performance of athletes – effect of speed endurance
training on ion handling and fatigue development. J. Physiol. 2017, 595, 2897–2913. [CrossRef] [PubMed]
2. Bangsbo, J. Performance in sports - With specific emphasis on the effect of intensified training. Scand. J. Med.
Sci. Sport 2015, 25, 88–99. [CrossRef] [PubMed]
3. Faria, E.W.; Parker, D.L.; Faria, I. The Science of Cycling. Sport Med. 2005, 35, 313–337. [CrossRef]
4. Laursen, P.B. Training for intense exercise performance: High-intensity or high-volume training? Scand. J.
Med. Sci. Sport 2010, 20, 1–10. [CrossRef] [PubMed]
5. Bishop, D.; Girard, O.; Méndez-Villanueva, A. Repeated-sprint ability part II: Recommendations for training.
Sport Med. 2011, 41, 741–756. [CrossRef]
6. Girard, O.; Mendez-Villanueva, A.; Bishop, D. Repeated-Sprint Ability – Part, I. Sport Med. 2011, 41, 673–694.
[CrossRef]
7. Capostagno, B.; Lambert, M.I.; Lamberts, R.P. A systematic review of Submaximal cycle tests to predict,
monitor, and optimize cycling performance. Int. J. Sports Physiol. Perform. 2016, 11, 707–714. [CrossRef]
8. Bouchard, C.; Rankinen, T. Individual differences in response to regular physical activity. Med. Sci. Sports
Exerc. 2001, 33, 446–451. [CrossRef]
9. Hautala, A.; Kiviniemi, A.M.; Mäkikallio, T.H.; Kinnunen, H.; Nissilä, S.; Huikuri, H.V.; Tulppo, M.P.
Individual differences in the responses to endurance and resistance training. Eur. J. Appl. Physiol. 2006, 96,
535–542. [CrossRef]
10. Schmitt, L.; Willis, S.; Fardel, A.; Coulmy, N.; Millet, G. Live high–train low guided by daily heart rate
variability in elite Nordic-skiers. Eur. J. Appl. Physiol. 2018, 118, 419–428. [CrossRef]
11. Aubert, A.E.; Seps, B.; Beckers, F. Heart Rate Variability in Athletes. Sport Med. 2003, 33, 889–919. [CrossRef]
[PubMed]
12. Chandola, T.; Heraclides, A.; Kumari, M. Psychophysiological biomarkers of workplace stressors.
Neurosci. Biobehav. Rev. 2010, 35, 51–57. [CrossRef] [PubMed]
13. Plews, D.J.; Laursen, P.B.; Stanley, J.; Kilding, A.E.; Buchheit, M. Training adaptation and heart rate variability
in elite endurance athletes: Opening the door to effective monitoring. Sport Med. 2013, 43, 773–781. [CrossRef]
[PubMed]
14. Rodas, G.; Pedret, C.; Ramos, J.; Capdevila, L. Heart rate variability: Definition, measurement and clinical
relation aspects (I). Arch. Med. Deport. 2008, 25, 41–47.
15. Huang, M.; Frantiz, J.; Moralez, G.; Sabo, T.; Davis, P.F.; Davis, S.L.; Bell, K.R.; Purkayastha, S. Reduced
Resting and Increased Elevation of Heart Rate Variability With Cognitive Task Performance in Concussed
Athletes. J. Head. Trauma Rehabil. 2018, 34, 45–51. [CrossRef]
16. Draghici, A.E.; Taylor, J.A. The physiological basis and measurement of heart rate variability in humans.
J. Physiol. Anthr. 2016, 35, 1–8. [CrossRef]
Int. J. Environ. Res. Public Health 2020, 17, 5465 11 of 12
17. Quintana, D.S.; Alvares, G.A.; Heathers, J.A.J. Guidelines for Reporting Articles on Psychiatry and Heart
rate variability (GRAPH): Recommendations to advance research communication. Transl. Psychiatry 2016, 6,
e803–e810. [CrossRef]
18. García-Manso, J. Aplicación de la variabilidad de la frecuencia cardiaca al control del entrenamiento deportivo:
Análisis en modo frecuencia. Arch. Med. Deport. 2013, 30, 43–51.
19. Parrado, E.; Cervantes, J.; Pintanel, M.; Rodas, G.; Capdevila, L. Perceived tiredness and heart rate variability
in relation to overload during a field hockey world cup. Percept. Mot. Ski. 2010, 110, 699–713. [CrossRef]
20. Lagos, L.; Vaschillo, E.; Vaschillo, B.; Lehrer, P.; Bates, M.; Pandina, R. Heart Rate Variability Biofeedback as a
Strategy for Dealing with Competitive Anxiety: A Case Study. Assoc. Appl. Psychophysiol. Biofeedback 2006,
36, 109–115.
21. Ortigosa-Márquez, J.; Reigal, R.; Portell, M.; Morales-Sánchez, V.; Hernández-Mendo, A. Observación
automatizada: La variabilidad de la frecuencia cardíaca y su relación con las variables psicológicas
determinantes del rendimiento en nadadores jóvenes. Anal. Psicol. 2017, 33, 436–441. [CrossRef]
22. Seiler, S.; Haugen, O.; Kuffel, E. Autonomic recovery after exercise in trained athletes: Intensity and duration
effects. Med. Sci. Sports Exerc. 2007, 39, 1366–1373. [CrossRef] [PubMed]
23. Hedelin, R.; Wiklund, U.; Bjerle, P.; Henriksson-Larsen, K. Cardiac autonomic imbalance in an overtrained
athlete. Med. Sci. Sports Exerc. 2000, 32, 1531–1533. [CrossRef] [PubMed]
24. Javaloyes, A.; Sarabia, J.; Lamberts, R.; Moya-Ramon, M. Training Prescription Guided by Heart Rate
Variability in Cycling. Int. J. Sports Physiol. Perform. 2019, 14, 23–32. [CrossRef]
25. Moreno, J.; Parrado, E.; Capdevila, L. Variabilidad de la frecuencia cardíaca y perfiles psicofisiológicos en
deportes de equipo de alto rendimiento. Rev. Psicol. Deport. 2013, 22, 345–352.
26. Ortigosa-Márquez, J.; Reigal, R.; Carranque, G.; Hernández-Mendo, A. Variabilidad de la frecuencia cardíaca:
Investigación y aplicaciones prácticas para el control de los procesos adaptativos en el deporte. Rev. Iberoam.
Psicol. Del. Ejerc. y el. Deport. 2018, 13, 121–130.
27. Martín-Guillaumes, J.; Caparrós, T.; Cruz-Puntí, D.; Montull, L.; Orriols, G.; Capdevila, L. Psicofisiologycal
monitoring of the recovery process in the elite athletes of the Spanish National Ski Mountaineering Team
through the RMSSD and the subjective perception of recovery. Rev. Iberoam. Psicol. Del. Ejerc. Y El. Deport
2018, 13, 219–223.
28. Da Silva, D.F.; Ferraro, Z.M.; Adamo, K.B.; Machado, F.A. Endurance running Training Individually Guided
by HRV in untrained Women. J. Strength Cond. Res. 2019, 33, 736–746. [CrossRef]
29. Kiviniemi, A.M.; Hautala, A.J.; Kinnunen, H.; Nissilä, J.; Virtanen, P.; Karjalainen, J.; Tulppo, M.P. Daily
exercise prescription on the basis of hr variability among men and women. Med. Sci. Sports Exerc. 2010, 42,
1355–1363. [CrossRef]
30. Nuuttila, O.; Nikander, A.; Polomoshnov, D.; Laukkanen, J.; Häkkinen, K. Effects of HRV-Guided vs.
Predetermined Block Training on Performance, HRV and Serum Hormones. Int. J. Sports Med. 2017, 38,
909–920. [CrossRef]
31. Vesterinen, V.; Nummela, A.; Heikura, I.; Laine, T.; Hynynen, E.; Botella, J.; Häkkinen, K. Individual
Endurance Training Prescription with Heart Rate Variability. Med. Sci. Sport Exerc. 2016, 48, 1347–1354.
[CrossRef] [PubMed]
32. Chan, A.-W.; Tetzlaff, J.M.; Gotzsche, P.C.; Altman, D.G.; Mann, H.; Berlin, J.A.; Dickersin, K.; Hrobjartsson, A.;
Schulz, K.F.; Parulekar, W.R.; et al. SPIRIT 2013 explanation and elaboration: Guidance for protocols of
clinical trials. BMJ 2013, 346, e7586. [CrossRef] [PubMed]
33. Hoffmann, T.C.; Glasziou, P.P.; Boutron, I.; Milne, R.; Perera, R.; Moher, D.; Altman, D.G.; Barbour, V.;
Macdonald, H.; Johnston, M.; et al. Better reporting of interventions: Template for intervention description
and replication (TIDieR) checklist and guide. BMJ 2014, 348, g1687. [CrossRef] [PubMed]
34. Kiviniemi, A.M.; Hautala, A.J.; Kinnunen, H.; Tulppo, M.P. Endurance training guided individually by daily
heart rate variability measurements. Eur. J. Appl. Physiol. 2007, 101, 743–751. [CrossRef] [PubMed]
35. Lamberts, R.P.; Swart, J.; Noakes, T.D.; Lambert, M.I. Changes in heart rate recovery after high-intensity
training in well-trained cyclists. Eur. J. Appl. Physiol. 2009, 105, 705–713. [CrossRef]
36. Plews, D.J.; Scott, B.; Altini, M.; Wood, M.; Kilding, A.E.; Laursen, P.B. Comparison of Heart-Rate-Variability
Recording With Smartphone Photoplethysmography, Polar H7 Chest Strap, and Electrocardiography.
Int. J. Sports Physiol. Perform. 2017, 12, 1324–1328. [CrossRef]
Int. J. Environ. Res. Public Health 2020, 17, 5465 12 of 12
37. Plews, D.J.; Laursen, P.B.; Kilding, A.E.; Buchheit, M. Evaluating Training Adaptation with Heart-Rate
Measures: A Methodological Comparison. Int. J. Sports Physiol. Perform. 2013, 8, 688–691. [CrossRef]
38. Plews, D.J.; Laursen, P.B.; Kilding, A.E.; Buchheit, M. Heart rate variability in elite triathletes, is variation
in variability the key to effective training? A case comparison. Eur. J. Appl. Physiol. 2012, 112, 3729–3741.
[CrossRef]
39. Ramírez, R.; Agredo, R.; Ortega, J.G.; Dosman, V.A.; López, C.A. Análisis comparativo del VO 2máx estimado
mediante las ecuaciones desarrolladas por Jackson et al. y el American College of Sport Medicine en
corredores de maratón. Apunt. Med. L’esport. 2009, 44, 57–65. [CrossRef]
40. Ballesta-García, I.; Martínez-González-Moro, I.; Ramos-Campo, D.J.; Carrasco-Poyatos, M. High-intensity
interval circuit training versus moderate-intensity continuous training on cardiorespiratory fitness in
middle-aged and older women: A randomized controlled trial. Int. J. Env. Res. Public Health 2020, 17, 1805.
[CrossRef]
41. Howley, E.T.; Bassett, D.R.; Welch, H.G. Criteria for maximal oxygen uptake. Med. Sci. Sport Exerc. 1995, 27,
1292–1301. [CrossRef]
42. Drew, B.; Califf, R.; Funk, M.; Kaufman, E.; Krucoff, M.; Laks, M.; Macfarlane, P.; Sommargren, C.; Swiryn, S.;
Van Hare, G.; et al. Aha scientific statement: Practice standars for electrocardiographic monitoring in hospital
settings: An american heart association scientific statement from the councils on cardiovascular nursing,
clinical cardiology, and cardiovascular disease in the yo. J. Cardiovasc. Nurs. 2005, 20, 76–106. [CrossRef]
[PubMed]
43. Clemente-Suárez, V.; Delgado-Moreno, R.; González, B.; Ortega, J.; Ramos-Campo, D. Amateur endurance
triathletes’ performance is improved independently of volume or intensity based training. Physiol. Behav.
2019, 205, 2–8. [CrossRef]
44. Luque-Casado, A.; Zabala, M.; Morales, E.; Mateo-March, M.; Sanabria, D. Cognitive Performance and Heart
Rate Variability: The Influence of Fitness Level. PLoS ONE 2013, 8, e56935. [CrossRef]
45. Ribas, J. Lactato: De indeseable a valioso metabolito. Arch. Med. Deport. 2010, 27, 211–230.
46. Rodríguez, M.; Valero, A. Efecto de una intervención ACT sobre la resistencia aeróbica y evitación experiencial
en marchistas Effect of an ACT Intervention on Aerobic Endurance and Experiential Avoidance in Walkers.
Rev. Costarric. Psicol. 2015, 34, 97–111.
47. Foster, C.; Florhaug, J.A.; Franklin, J.; Gottschall, L.; Hrovatin, L.A.; Parker, S.; Doleshal, P.; Dodge, C. A New
Approach to Monitoring Exercise Training. J. Strenght Cond. Res. 2001, 15, 109–115. [CrossRef]
48. Haddad, M.; Stylianides, G.; Djaoui, L.; Dellal, A.; Chamari, K. Session-RPE Method for Training Load
Monitoring: Validity, Ecological Usefulness, and Influencing Factors. Front. Neurosci. 2017, 11, 612.
[CrossRef]
49. Hopkins, W.G.; Marshall, S.W.; Batterham, A.M.; Hanin, J. Progressive Statistics for Studies in Sports Medicine
and Exercise Science. Med. Sci. Sport Exerc. 2009, 41, 3–13. [CrossRef]
50. Javaloyes, A.; Sarabia, J.M.; Lamberts, R.P.; Plews, D.; Moya-Ramon, M. Training Prescription Guided by
Heart Rate Variability Vs. Block Periodization in Well-Trained Cyclists. J. Strength Cond. Res. 2020, 34,
1511–1518. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
